SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
YM BioSciences: Trading Below Cash with Multiple Catalysts
AMGN
|
|
|
-9.59%
in
93 days
YM BioSciences (AMEX:YMI) (TSE:YM) (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on a fully diluted basis, which equates to a market cap of about US$34M and US$38M, respectively. <o:p> </o:p> http://biomedreports.com/articles/most-popular/5071-ym-biosci... <o:p> </o:p> <> Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting mo...
|
FDA Calendar Updates: Acorda, Amgen, DOR BioPharma
AMGN
|
|
|
-4.77%
in
4 days
(closed on 08/08/09)
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 290 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial result...
|
Amgen 2Q Earnings Beat, Raises Guidance, Denosumab Deal
AMGN
|
|
|
+4.53%
in
8 days
(closed on 08/04/09)
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1% during 2Q09 to $3.71 billion versus $3.76 billion during 2Q08. The Company provided revenue guidance for 2009 that is trending towards the upper end of its current guidance range of $14.4-14.8 billion. Amgen now expects 2009 adjusted EPS to be in the range of $4.80-4.95, an increase from the previous range of $4.55 to $4.75. The Company no...
|
FDA Calendar: 2H09 Binary Event Trades
AMGN
|
|
|
-0.25%
in
1 day
(closed on 07/27/09)
<> Below is a selection of companies included in the BioMedReports.com FDA Calendar database of 281 entries as of 7/26/09 with expected binary event catalysts through year-end. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the ...
|
FDA Calendar Updates: Amgen, Bayer, Biogen, Noveko, Peplin, Transdel
AMGN
|
|
|
+0.63%
in
18 days
(closed on 07/26/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 246 entries as of 7/8/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending...
|
From the Blogosphere
Nasdaq Market Wrap 1 November
The 60-minute trend is down according to the force index indicator. %b has printed a slightly positive divergence. Finally prices have moved quickly to the downside. The Nasdaq is underperforming the Dow and the S&P. In fact, the breakout of the rising trendline has already occurred. On Thursday prices retested the trendline and Friday accelerated to the downsode quite impressively. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. I would expect overall a negative week. Many stocks have printed new 20-day low. I remain negative on...
|
Nasdaq Market Wrap 1 November
|
|
|
The 60-minute trend is down according to the force index indicator. %b has printed a slightly positive divergence. Finally prices have moved quickly to the downside. The Nasdaq is underperforming the Dow and the S&P. In fact, the breakout of the rising trendline has already occurred. On Thursday prices retested the trendline and Friday accelerated to the downsode quite impressively. Support at 1650. Then 1590. Prices are now testing the lower trendline of a channel that prices are forming. I would expect overall a negative week. Many stocks have printed new 20-day low. I remain negative on...
|
Nasdaq Market Wrap 25 Oct
|
|
|
The 60-minute trend is down according to the force index indicator. %b has printed a slightly negative divergence. The Nasdaq has managed to print new highs, but actually momentum is very low. Support at 1740. Prices are moving within within a slightly positevely inclined channel. Prices are now testing the lower trendline. I would expect a negative week. Many stocks are still trading above their 20-day moving averages, but the picture is more mixed than last week. Actually only MSFT and AMZN printed a 20-day high on Friday. AMGN, BRCM, CMCSA, DISH, GILD, JAVA, NVDA, QCOM printed a new ...
|
Nasdaq Market Wrap 25 Oct
The 60-minute trend is down according to the force index indicator. %b has printed a slightly negative divergence. The Nasdaq has managed to print new highs, but actually momentum is very low. Support at 1740. Prices are moving within within a slightly positevely inclined channel. Prices are now testing the lower trendline. I would expect a negative week. Many stocks are still trading above their 20-day moving averages, but the picture is more mixed than last week. Actually only MSFT and AMZN printed a 20-day high on Friday. AMGN, BRCM, CMCSA, DISH, GILD, JAVA, NVDA, QCOM printed a new ...
|
Cord Blood Stocks: Cord Blood Transplants May Provide Cures for Babies While Still in the Womb
|
|
|
Duke University is studying the use of cord blood transplants in babies while still in the womb, in order to treat various metabolic disorders. The U.S. Food and Drug Administration has given approval for clinical trials.
Cord blood is blood that comes from umbilical cords, and contains a large amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Many parents have their newborn's cord blood preserved in the event it may be needed at some point in the future for tr...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AMGN |
Visit streetinsider.com
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
More Resources
|
About Amgen Inc
- Answers.com
